Arca
Skip to content
Tools
Tools

PBPA: Cell shape peptidoglycan synthetase penicillin-binding protein 2

Protein in Escherichia coli that 1 drug acts on.

  • Drugs that act on it: 1
  • Approved: 1
  • In phases 1 to 3: 0
  • Sponsors: 1

Who is on it, and how far along

Every drug ChEMBL records acting on PBPA, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 1

Approved1

  • Ertapenem

Phase 30

    Phase 20

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        DrugFurthest stageSponsorModalityActionOpen trials
        ErtapenemApprovedMerck & Co. (MSD)Small moleculeInhibitorCell shape peptidoglycan synthetase penicillin-binding protein 2 inhibitor12

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
        This is a Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ertapenem-zidebactam Versus Ceftazidime-Avibactam in the Treatment of Hospitalized Adult Patients With Complicated Urinary Tract Infection or Acute PyelonephritisErtapenemPhase 2Not yet recruitingWockhardtSep 24, 2026
        Combination Antibiotic Therapy for Staphylococcus Aureus BacteremiaErtapenemPhase 4RecruitingIntermountain Health Care, Inc.Jan 29, 2026
        Cefotetan Therapy for Escherichia Coli InfectionsErtapenemPhase 2RecruitingOregon Health and Science UniversityJan 6, 2026
        Pivmecillinam as Oral Step-Down Treatment for Escherichia Coli Febrile Urinary Tract Infection Versus Standard of CareErtapenemPhase 4RecruitingUppsala UniversityNov 19, 2025
        Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes?ErtapenemPhase 4Enrolling by invitationWest Virginia UniversityAug 29, 2025
        PRevention Of Trauma-related Infections Through an Embedded Clinical Trials NetworkErtapenemPhase 4Not yet recruitingThe University of Texas Health Science Center, HoustonApr 9, 2025
        A Platform Trial for Gram Negative Bloodstream InfectionsErtapenemNot applicableRecruitingSunnybrook Health Sciences CentreAug 5, 2024
        Pivmecillinam With Amoxicillin/Clavulanic Acid for Step Down Oral Therapy in ESBL UTIsErtapenemPhase 3RecruitingLund UniversityFeb 4, 2022

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3309036, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.